Successful embryo cryopreservation immediately following a full-term delivery in a woman with newly diagnosed Ewing’s sarcoma

  • Emma Giuliani
  • Erin M. Ellman
  • Rashmi Chugh
  • Molly B. MoravekEmail author
Fertility Preservation


Ewing’s sarcoma is an aggressive, small blue round cell malignancy, affecting one per million people in the USA [1]. Albeit extremely rare, the incidence is much higher in children and young adults, a population who often have not completed their child-bearing. In fact, it accounts for approximately 10% of malignant bone cancers in children and young adults, and 3% of all childhood malignancies [1]. Unfortunately, 25% of patients who present with a clinically apparent localized tumor may also already have signs of occult metastatic disease [2]. Most commonly, metastases are found in the lungs, bones, and bone marrow [2].

While surgery remains a fundamental treatment strategy, the introduction of new chemotherapy agents and the combination of chemo and local radiotherapy (conformational RT and intensity-modulated RT) have led to increased 5-year survival rates from less than 15% to 65–70% for patients with localized disease and to 25–30% for those with metastatic disease [1...


Compliance with ethical standards

Informed consent was obtained from the patient described in this case report.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Lahl M, Fisher VL, Laschinger K. Ewing’s sarcoma family of tumors: an overview from diagnosis to survivorship. Clin J Oncol Nurs. 2008;12:89–97.CrossRefGoogle Scholar
  2. 2.
    Grünewald TGP, Cidre-Aranaz F, Surdez D, Tomazou EM, de Álava E, Kovar H, et al. Ewing sarcoma. Nat Rev Dis Primers. 2018;5:5.CrossRefGoogle Scholar
  3. 3.
    Zhang T, Zhang S, Yang F, Wang L, Zhu S, Qiu B, et al. Efficacy comparison of six chemotherapeutic combinations for osteosarcoma and Ewing’s sarcoma treatment: a network meta-analysis. J Cell Biochem. 2018;119:250–9.CrossRefGoogle Scholar
  4. 4.
    Donnez J, Dolmans MM. Fertility preservation in women. Nat Rev Endocrinol. 2013;9:735–49.CrossRefGoogle Scholar
  5. 5.
    Cakmak H, Rosen MP. Random-start ovarian stimulation in patients with cancer. Curr Opin Obstet Gynecol. 2015;27:215–21.CrossRefGoogle Scholar
  6. 6.
    Combination chemotherapy with or without ganitumab in treating patients with newly diagnosed metastatic Ewing sarcoma. (2018). Retrieved from (Identification No. NCT02306161).
  7. 7.
    Vu JV, Llarena NC, Estevez SL, Moravek MB, Jeruss JS. Oncofertility program implementation increases access to fertility preservation options and assisted reproductive procedures for breast cancer patients. J Surg Oncol. 2017;115:116–21.CrossRefGoogle Scholar
  8. 8.
    Pankhurst MW, Clark CA, Zarek J, Laskin CA, McLennan IS. Changes in circulating ProAMH and total AMH during healthy pregnancy and post-partum: a longitudinal study. PLoS One. 2016;11(9):e0162509.CrossRefGoogle Scholar
  9. 9.
    Goeckenjan M, Rösner S, Toth B, Strowitzki T, Germeyer A. Successful controlled ovarian stimulation despite elevated hCG levels after first-trimester abortion in the context of fertility preservation. Gynecol Endocrinol. 2013;29:960–2.CrossRefGoogle Scholar
  10. 10.
    Cohade C, Moreau J, Gatimel N, Gladieff L, Parinaud J, Leandri R. Follicular growth but absence of oocyte and cumulus maturation during ovarian stimulation in the days following surgical abortion: a case report. Gynecol Endocrinol. 2017;33:680–1.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Emma Giuliani
    • 1
  • Erin M. Ellman
    • 1
  • Rashmi Chugh
    • 2
  • Molly B. Moravek
    • 1
    Email author
  1. 1.Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and GynecologyUniversity of MichiganAnn ArborUSA
  2. 2.Division of Hematology and Oncology, Department of Internal MedicineUniversity of MichiganAnn ArborUSA

Personalised recommendations